Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-nectin-4 antibody-drug conjugate 9MW2821

An antibody drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically conjugated, via a linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-nectin-4 ADC 9MW2821, the anti-nectin-4 antibody targets and binds to nectin-4 expressed on tumor cells. Upon binding and internalization, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4-expressing tumor cells. Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC 9MW2821
anti-Nectin-4 ADC 9MW2821
anti-nectin-4/MMAE ADC 9MW2821
Code name:9MW 2821
9MW-2821
9MW2821
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search